Are you over 18 and want to see adult content?
More Annotations
A complete backup of globeontheweb.com
Are you over 18 and want to see adult content?
A complete backup of buymixcloudplays.com
Are you over 18 and want to see adult content?
A complete backup of maxmedien-akademie.at
Are you over 18 and want to see adult content?
A complete backup of kia-aldjazair.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of rodriguezmorales.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of learninghouse.ca
Are you over 18 and want to see adult content?
A complete backup of fitnessandleisure.co.nz
Are you over 18 and want to see adult content?
A complete backup of picscannergold.com
Are you over 18 and want to see adult content?
A complete backup of activatecodess.com
Are you over 18 and want to see adult content?
A complete backup of ideaandcreativity.com
Are you over 18 and want to see adult content?
A complete backup of cinetecamadrid.com
Are you over 18 and want to see adult content?
A complete backup of operationquickmoney.net
Are you over 18 and want to see adult content?
Text
ASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community MEDICARE SEQUESTRATION DELAY EXTENDED THROUGH 2021 As part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, this automatic 2% cut to all Medicare providers was temporarily halted in 2020, then extended through March 2021. Although the Medicare sequestration delay expired in early April, the Centers for Medicare & Medicaid Services (CMS) had not been enforcing the 2% cut. PREDICTING CAR T-CELL TREATMENT FAILURE IN PATIENTS WITH Nearly one-half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are treated with chimeric antigen receptor (CAR) T-cell therapy experience a relapse within one month of infusion, according to research published in Blood Advances.Study authors also established a set of risk factors for early progression, including number of extranodal sites and total metabolic CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz DRUG PRICES INCREASE 5% IN 2021 Drug Prices Increase 5% in 2021. Wednesday, January 13, 2021. A new analysis by market research firm 46brooklyn found that the median wholesale price for 645 brand-name medicines in the U.S. increased 4.8% on January 1, 2021, as pharmaceutical companies announced new drug prices for the beginning of the year. However, this figure couldchange
TPO-RAS AND ITP: ELTROMBOPAG INDUCES HIGH EFFICACY, BUT A pair of studies presented at the 2020 American Society of Hematology Annual Meeting analyzed the thrombopoietin receptor agonist (TPO-RA) eltrombopag in two settings: in real-world clinical practice against clinical trials experiences, and against another TPO-RA, avatrombopag. WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News PRESCRIBING OPTIONS IN THE CASE OF ANTICOAGULATION FAILURE It is clearly a failure of apixaban. As in any other rare case of failure of anticoagulant therapy, provided the chosen drug was effectively administrated, my main concern is to diagnose the condition that leads to recurrence.ASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community MEDICARE SEQUESTRATION DELAY EXTENDED THROUGH 2021 As part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, this automatic 2% cut to all Medicare providers was temporarily halted in 2020, then extended through March 2021. Although the Medicare sequestration delay expired in early April, the Centers for Medicare & Medicaid Services (CMS) had not been enforcing the 2% cut. PREDICTING CAR T-CELL TREATMENT FAILURE IN PATIENTS WITH Nearly one-half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are treated with chimeric antigen receptor (CAR) T-cell therapy experience a relapse within one month of infusion, according to research published in Blood Advances.Study authors also established a set of risk factors for early progression, including number of extranodal sites and total metabolic CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz DRUG PRICES INCREASE 5% IN 2021 Drug Prices Increase 5% in 2021. Wednesday, January 13, 2021. A new analysis by market research firm 46brooklyn found that the median wholesale price for 645 brand-name medicines in the U.S. increased 4.8% on January 1, 2021, as pharmaceutical companies announced new drug prices for the beginning of the year. However, this figure couldchange
TPO-RAS AND ITP: ELTROMBOPAG INDUCES HIGH EFFICACY, BUT A pair of studies presented at the 2020 American Society of Hematology Annual Meeting analyzed the thrombopoietin receptor agonist (TPO-RA) eltrombopag in two settings: in real-world clinical practice against clinical trials experiences, and against another TPO-RA, avatrombopag. WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News PRESCRIBING OPTIONS IN THE CASE OF ANTICOAGULATION FAILURE It is clearly a failure of apixaban. As in any other rare case of failure of anticoagulant therapy, provided the chosen drug was effectively administrated, my main concern is to diagnose the condition that leads to recurrence. DRUG PRICES INCREASE 5% IN 2021 Drug Prices Increase 5% in 2021. Wednesday, January 13, 2021. A new analysis by market research firm 46brooklyn found that the median wholesale price for 645 brand-name medicines in the U.S. increased 4.8% on January 1, 2021, as pharmaceutical companies announced new drug prices for the beginning of the year. However, this figure couldchange
THE HIGH PRICE OF HEMOPHILIA The High Price of Hemophilia. Saturday, February 1, 2020. An estimated 20,000 people in the U.S. are living with the inherited bleeding disorder hemophilia, and more than 60% of them have moderate or severe hemophilia requiring lifelong treatment with expensive drugs and clotting factors. 1. The good news is that these treatments work. VENETOCLAX AND AZACITIDINE COMBINATION ASSOCIATED WITH More than three-quarters of patients with higher-risk, treatment-naïve myelodysplastic syndromes (MDS) responded to the combination of venetoclax plus azacitidine, according to study results presented during the 2020 ASH Annual Meeting by Jacqueline Garcia, MD, of the Dana-Farber Cancer Institute. The combination also led to improvements in patient-reported outcomes, such as FDA CLEARS IND APPLICATION FOR GAMMA DELTA T-CELL THERAPY The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for GDX012 to be examined as a therapy for patients with hematologic malignancies. OLUTASIDENIB SHOWS PROMISE FOR RELAPSED/REFRACTORY IDH1 Olutasidenib, an investigational IDH1 inhibitor selective for mutant IDH1, was well tolerated and associated with durable complete remissions (CRs) in patients with high-risk, relapsed/refractory IDH1-mutated acute myeloid leukemia (AML), according to interim findings from a phase II trial presented at the 2021 American Society of Clinical Oncology Annual Meeting. FIXED-DURATION IBRUTINIB, VENETOCLAX ORAL COMBINATION A fixed-duration regimen of first-line ibrutinib plus venetoclax provided deep, durable responses in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results of the phase-2 CAPTIVATE study presented at the 2021 American Society of Clinical Oncology Annual Meeting. WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News EVALUATING EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE Treatment with the neonatal Fc receptor antagonist efgartigimod led to clinically relevant increases in platelet counts in patients with primary immune thrombocytopenia (ITP), according to results from a small phase II trial published in the American Journal of Hematology.Treatment also was associated with lower bleeding rates, the authors, led by Adrian C. Newland, MD, from the Centre for MULTIPLE MYELOMA ARCHIVES Visit our Multiple Myeloma category - Page 13 of 13. ASH Clinical News. Contact us today ON LOCATION ARCHIVES Visit our On Location category - Page 51 of 51. ASH Clinical News.Contact us today
ASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community OLDER PATIENTS WITH MYELOMA MAY HAVE SUBOPTIMAL RESPONSE Reference. Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose Blood. doi: 10.1182/blood.2021011904. MEDICARE SEQUESTRATION DELAY EXTENDED THROUGH 2021 Monday, April 26, 2021. The U.S. House of Representatives voted 384-38 in favor of continuing to delay the return of Medicare sequestration. As part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, this automatic 2% cut to all Medicare providers was temporarily halted in 2020, then extended through March 2021. FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz PREDICTING CAR T-CELL TREATMENT FAILURE IN PATIENTS WITH Nearly one-half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are treated with chimeric antigen receptor (CAR) T-cell therapy experience a relapse within one month of infusion, according to research published in Blood Advances.Study authors also established a set of risk factors for early progression, including number of extranodal sites and total metabolic IBERDOMIDE: A NEW IMMUNOMODULATORY DRUG FOR HEAVILY Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma. Monday, June 3, 2019. One-third of patients with relapsed/refractory multiple myeloma (MM) responded to treatment with the investigational agent iberdomide, according to early results from a first-in-human trial. Sagar Lonial, MD, from the Winship CancerInstitute of Emory
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITH The findings, though, appear to raise more questions than they answer. While individuals with MGUS had normal bone-mineral density (BMD), their bone volume was increased compared to patients without MGUS. In addition, men with MGUS had an almost 50% increased risk of fractures, compared with other men. “Our findings suggest an effect of MGUS PRESCRIBING OPTIONS IN THE CASE OF ANTICOAGULATION FAILURE It is clearly a failure of apixaban. As in any other rare case of failure of anticoagulant therapy, provided the chosen drug was effectively administrated, my main concern is to diagnose the condition that leads to recurrence.ASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community OLDER PATIENTS WITH MYELOMA MAY HAVE SUBOPTIMAL RESPONSE Reference. Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose Blood. doi: 10.1182/blood.2021011904. MEDICARE SEQUESTRATION DELAY EXTENDED THROUGH 2021 Monday, April 26, 2021. The U.S. House of Representatives voted 384-38 in favor of continuing to delay the return of Medicare sequestration. As part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, this automatic 2% cut to all Medicare providers was temporarily halted in 2020, then extended through March 2021. FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz PREDICTING CAR T-CELL TREATMENT FAILURE IN PATIENTS WITH Nearly one-half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are treated with chimeric antigen receptor (CAR) T-cell therapy experience a relapse within one month of infusion, according to research published in Blood Advances.Study authors also established a set of risk factors for early progression, including number of extranodal sites and total metabolic IBERDOMIDE: A NEW IMMUNOMODULATORY DRUG FOR HEAVILY Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma. Monday, June 3, 2019. One-third of patients with relapsed/refractory multiple myeloma (MM) responded to treatment with the investigational agent iberdomide, according to early results from a first-in-human trial. Sagar Lonial, MD, from the Winship CancerInstitute of Emory
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITH The findings, though, appear to raise more questions than they answer. While individuals with MGUS had normal bone-mineral density (BMD), their bone volume was increased compared to patients without MGUS. In addition, men with MGUS had an almost 50% increased risk of fractures, compared with other men. “Our findings suggest an effect of MGUS PRESCRIBING OPTIONS IN THE CASE OF ANTICOAGULATION FAILURE It is clearly a failure of apixaban. As in any other rare case of failure of anticoagulant therapy, provided the chosen drug was effectively administrated, my main concern is to diagnose the condition that leads to recurrence. OLDER PATIENTS WITH MYELOMA MAY HAVE SUBOPTIMAL RESPONSE Reference. Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose Blood. doi: 10.1182/blood.2021011904. ASH PRESENTS FAQ RESOURCE FOR THROMBOSIS WITH New COVID-19 Resource: FAQ About Thrombosis with Thrombocytopenia Syndrome. The American Society of Hematology (ASH) has released a resource to guide clinicians in recognizing and treating thrombosis with thrombocytopenia syndrome (TTS), also termed vaccine-induced thrombotic thrombocytopenia (VITT), which is the rare clotting condition reported in several individuals after FIXED-DURATION IBRUTINIB, VENETOCLAX ORAL COMBINATION A fixed-duration regimen of first-line ibrutinib plus venetoclax provided deep, durable responses in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results of the phase-2 CAPTIVATE study presented at the 2021 American Society of Clinical Oncology Annual Meeting. OLUTASIDENIB SHOWS PROMISE FOR RELAPSED/REFRACTORY IDH1 Olutasidenib, an investigational IDH1 inhibitor selective for mutant IDH1, was well tolerated and associated with durable complete remissions (CRs) in patients with high-risk, relapsed/refractory IDH1-mutated acute myeloid leukemia (AML), according to interim findings from a phase II trial presented at the 2021 American Society of Clinical Oncology Annual Meeting. EARLY TRIAL SHOWS PROMISING RESULTS FOR VENETOCLAX Adding venetoclax to rituximab and lenalidomide appeared to be safe and resulted in high rates of overall response and measurable residual disease (MRD) undetectability in patients with newly diagnosed mantle cell lymphoma (MCL), according to the results from a phase Ib study presented at the 2021 American Society of Clinical Oncology AnnualMeeting.
VENETOCLAX AND AZACITIDINE COMBINATION ASSOCIATED WITH More than three-quarters of patients with higher-risk, treatment-naïve myelodysplastic syndromes (MDS) responded to the combination of venetoclax plus azacitidine, according to study results presented during the 2020 ASH Annual Meeting by Jacqueline Garcia, MD, of the Dana-Farber Cancer Institute. The combination also led to improvements in patient-reported outcomes, such as LUNG DRUG TOXICITY TAZEMETOSTAT 2021 L Street NW, Suite 900, Washington, DC 20036 Phone 202-776-0544 |Fax 202-776-0545
ADDING MYCOPHENOLATE TO In results from the randomized, controlled FLIGHT trial, patients with immune thrombocytopenia (ITP) who received mycophenolate mofetil (MMF) plus corticosteroids as first-line therapy were more likely to respond to treatment, compared with PET-ADAPTED THERAPY IN CLASSICAL HODGKIN LYMPHOMA ALLOWS Patients with early-stage classical Hodgkin lymphoma (cHL) and bulky disease who achieved a response after two cycles of chemotherapy were able to avoid radiation therapy, while escalated therapy led to noninferior outcomes in those who did not have an initial response, according to results from the Alliance for Clinical Trials in Oncology’s CALGB-50801 trial. MULTIPLE MYELOMA ARCHIVES Visit our Multiple Myeloma category - Page 13 of 13. ASH Clinical News. Contact us todayASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITHBLOOD DISORDER MGUSLIFE EXPECTANCY FOR MGUS PATIENTSMGUS BLOOD CONDITIONMGUS SYMPTOMS FATIGUESIGNS THAT MGUS IS PROGRESSINGSYMPTOMS OF MGUS DISEASE The findings, though, appear to raise more questions than they answer. While individuals with MGUS had normal bone-mineral density (BMD), their bone volume was increased compared to patients without MGUS. In addition, men with MGUS had an almost 50% increased risk of fractures, compared with other men. “Our findings suggest an effect of MGUS R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News WILL REPLACING BLEOMYCIN WITH BRENTUXIMAB VEDOTIN For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen and replacing it with brentuximab vedotin and AVD (A+AVD) could prolong modified progression-free survival (mPFS). MORE REASONS TO BECOME A HEMATOLOGIST… More Reasons to Become a Hematologist. Sunday, May 1, 2016. In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology). After sharing the results of an entirely non-scientific survey of hiscolleagues
PATIENT EDUCATION UNDERSTANDING VON WILLEBRAND DISEASEHOW TO DIAGNOSE VON WILLEBRAND DISEASESYMPTOMS OF VON WILLEBRAND DISEASEVON WILLEBRAND DISEASE UPTODATEVON WILLEBRAND DISEASE IN CHILDRENVON WILLEBRAND DISEASE IN DOGSVON WILLEBRAND DISEASE IN GIRLS What Are the Symptoms of vWD? People with vWD experience frequent nosebleeds, easy bruising, and excessive bleeding during and after inva-sive procedures, such as tooth extractions and surgery. PATIENT EDUCATION WHAT IS MULTIPLE MYELOMA?PATIENT EDUCATION FOR NEWLYDIAGNOSED MULT…
What is Multiple Myeloma? Multiple myeloma starts in the plasma cells in bone mar-row. The bone marrow is the soft, spongy tissue found in the center of many bones where blood cells are produced.ASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITHBLOOD DISORDER MGUSLIFE EXPECTANCY FOR MGUS PATIENTSMGUS BLOOD CONDITIONMGUS SYMPTOMS FATIGUESIGNS THAT MGUS IS PROGRESSINGSYMPTOMS OF MGUS DISEASE The findings, though, appear to raise more questions than they answer. While individuals with MGUS had normal bone-mineral density (BMD), their bone volume was increased compared to patients without MGUS. In addition, men with MGUS had an almost 50% increased risk of fractures, compared with other men. “Our findings suggest an effect of MGUS R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News WILL REPLACING BLEOMYCIN WITH BRENTUXIMAB VEDOTIN For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen and replacing it with brentuximab vedotin and AVD (A+AVD) could prolong modified progression-free survival (mPFS). MORE REASONS TO BECOME A HEMATOLOGIST… More Reasons to Become a Hematologist. Sunday, May 1, 2016. In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology). After sharing the results of an entirely non-scientific survey of hiscolleagues
PATIENT EDUCATION UNDERSTANDING VON WILLEBRAND DISEASEHOW TO DIAGNOSE VON WILLEBRAND DISEASESYMPTOMS OF VON WILLEBRAND DISEASEVON WILLEBRAND DISEASE UPTODATEVON WILLEBRAND DISEASE IN CHILDRENVON WILLEBRAND DISEASE IN DOGSVON WILLEBRAND DISEASE IN GIRLS What Are the Symptoms of vWD? People with vWD experience frequent nosebleeds, easy bruising, and excessive bleeding during and after inva-sive procedures, such as tooth extractions and surgery. PATIENT EDUCATION WHAT IS MULTIPLE MYELOMA?PATIENT EDUCATION FOR NEWLYDIAGNOSED MULT…
What is Multiple Myeloma? Multiple myeloma starts in the plasma cells in bone mar-row. The bone marrow is the soft, spongy tissue found in the center of many bones where blood cells are produced. MEDICARE SEQUESTRATION DELAY EXTENDED THROUGH 2021 Monday, April 26, 2021. The U.S. House of Representatives voted 384-38 in favor of continuing to delay the return of Medicare sequestration. As part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, this automatic 2% cut to all Medicare providers was temporarily halted in 2020, then extended through March 2021. FDA CLEARS IND APPLICATION FOR GAMMA DELTA T-CELL THERAPY The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for GDX012 to be examined as a therapy for patients with hematologic malignancies. KATHI MOONEY: IMPACT OF REMOTE MONITORING ON PATIENTS WITH Kathi Mooney: Impact of Remote Monitoring on Patients with Cancer During the COVID-19 Pandemic - Exclusive Videos, Meeting Coverage, Multimedia, Non-ASH Meetings - ASH Clinical NewsPRINT SUBSCRIPTION
ASH Clinical News is your source for worldwide news and perspectives on hematology/oncology. Published 15 times per year, ASH Clinical News provides American Society of Hematology members and non-members alike with the latest updates in the field, including: To receive a complimentary print subscription of ASH Clinical News, click below. GENOME GENETICS DNA MOONSHOT PERSONALIZED TREATMENT 2021 L Street NW, Suite 900, Washington, DC 20036 Phone 202-776-0544 |Fax 202-776-0545
LETERMOVIR PREVENTS CYTOMEGALOVIRUS INFECTION AND IMPROVES Prophylactic treatment with letermovir improved overall survival (OS) and significantly decreased the incidence of clinically significant cytomegalovirus (CMV) infection in patients who underwent allogeneic hematopoietic cell transplantation (alloHCT), according to results from a single-center study presented at the 2021 American Society of Clinical Oncology Annual Meeting. HIGH IMMUNOGLOBULIN E LEVELS: A CAUSE FOR CONCERN IN During a mean follow-up of seven years, 3,454 participants were diagnosed with cancer. When researchers conducted a multivariable analyses of cancer incidence according to levels of IgE, they found that a 10-fold higher level of IgE conferred only a slightly higher risk of developing any cancer, but, as they hypothesized, wassignificantly
ACUTE LEUKEMIAS ARCHIVES Visit our Acute Leukemias category - Page 15 of 15. ASH Clinical News.Contact us today
ON LOCATION ARCHIVES Visit our On Location category - Page 50 of 50. ASH Clinical News.Contact us today
THE SIGNIFICANCE OF JAK2-POSITIVE TEST RESULTS IN A Majid Shojania, MD. Winnipeg, Canada. JAK2 mutation should not be present in the normal population; it is a sign of a hematologic condition but not specific. It is more common in patients with polycythemia vera or myelofibrosis but also can be seen in those with myelodysplastic syndromes (MDS) andASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITHBLOOD DISORDER MGUSLIFE EXPECTANCY FOR MGUS PATIENTSMGUS BLOOD CONDITIONMGUS SYMPTOMS FATIGUESIGNS THAT MGUS IS PROGRESSINGSYMPTOMS OF MGUS DISEASE The findings, though, appear to raise more questions than they answer. While individuals with MGUS had normal bone-mineral density (BMD), their bone volume was increased compared to patients without MGUS. In addition, men with MGUS had an almost 50% increased risk of fractures, compared with other men. “Our findings suggest an effect of MGUS R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News WILL REPLACING BLEOMYCIN WITH BRENTUXIMAB VEDOTIN For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen and replacing it with brentuximab vedotin and AVD (A+AVD) could prolong modified progression-free survival (mPFS). MORE REASONS TO BECOME A HEMATOLOGIST… More Reasons to Become a Hematologist. Sunday, May 1, 2016. In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology). After sharing the results of an entirely non-scientific survey of hiscolleagues
PATIENT EDUCATION UNDERSTANDING VON WILLEBRAND DISEASEHOW TO DIAGNOSE VON WILLEBRAND DISEASESYMPTOMS OF VON WILLEBRAND DISEASEVON WILLEBRAND DISEASE UPTODATEVON WILLEBRAND DISEASE IN CHILDRENVON WILLEBRAND DISEASE IN DOGSVON WILLEBRAND DISEASE IN GIRLS What Are the Symptoms of vWD? People with vWD experience frequent nosebleeds, easy bruising, and excessive bleeding during and after inva-sive procedures, such as tooth extractions and surgery. PATIENT EDUCATION WHAT IS MULTIPLE MYELOMA?PATIENT EDUCATION FOR NEWLYDIAGNOSED MULT…
What is Multiple Myeloma? Multiple myeloma starts in the plasma cells in bone mar-row. The bone marrow is the soft, spongy tissue found in the center of many bones where blood cells are produced.ASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITHBLOOD DISORDER MGUSLIFE EXPECTANCY FOR MGUS PATIENTSMGUS BLOOD CONDITIONMGUS SYMPTOMS FATIGUESIGNS THAT MGUS IS PROGRESSINGSYMPTOMS OF MGUS DISEASE Understanding Bone Disease and Fractures in Patients With MGUS - Blood Advances in a Different Vein, From the Blood Journals, News - ASHClinical News
R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News MORE REASONS TO BECOME A HEMATOLOGIST… In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology).After sharing the results of an entirely non-scientific survey of his colleagues (such as “I experienced a strange thrill after using the longest needles ever made” and “I misspelled WILL REPLACING BLEOMYCIN WITH BRENTUXIMAB VEDOTIN For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen and replacing it with brentuximab vedotin and AVD (A+AVD) could prolong modified progression-free survival (mPFS). PATIENT EDUCATION UNDERSTANDING VON WILLEBRAND DISEASEHOW TO DIAGNOSE VON WILLEBRAND DISEASESYMPTOMS OF VON WILLEBRAND DISEASEVON WILLEBRAND DISEASE UPTODATEVON WILLEBRAND DISEASE IN CHILDRENVON WILLEBRAND DISEASE IN DOGSVON WILLEBRAND DISEASE IN GIRLS What Are the Symptoms of vWD? People with vWD experience frequent nosebleeds, easy bruising, and excessive bleeding during and after inva-sive procedures, such as tooth extractions and surgery. PATIENT EDUCATION WHAT IS MULTIPLE MYELOMA?PATIENT EDUCATION FOR NEWLYDIAGNOSED MULT…
What is Multiple Myeloma? Multiple myeloma starts in the plasma cells in bone mar-row. The bone marrow is the soft, spongy tissue found in the center of many bones where blood cells are produced.PRINT SUBSCRIPTION
ASH Clinical News is your source for worldwide news and perspectives on hematology/oncology. Published 15 times per year, ASH Clinical News provides American Society of Hematology members and non-members alike with the latest updates in the field, including: To receive a complimentary print subscription of ASH Clinical News, click below. FDA BRINGS BACK UNAPPROVED DRUGS INITIATIVE The U.S. Food and Drug Administration (FDA) is reversing the Trump administration’s decision to end the Unapproved Drugs Initiative. This program, which launched in 2006, requires pharmaceutical manufacturers to seek approval for drugs that were never approved but were on the market because they predated stricter regulatoryrequirements.
GENOME GENETICS DNA MOONSHOT PERSONALIZED TREATMENT 2021 L Street NW, Suite 900, Washington, DC 20036 Phone 202-776-0544 |Fax 202-776-0545
BIDEN ADMINISTRATION REQUESTS $13.5 BILLION INCREASE IN As part of the administration’s $6 trillion budget request for the 2022 fiscal year, President Joe Biden has proposed a 9% increase, or $13.5 billion, in federal spending on research and development. This includes an increase of 10%, or $4.4 billion, in spending on basic research and 14%, or $6.3 billion, on applied research. HIGH IMMUNOGLOBULIN E LEVELS: A CAUSE FOR CONCERN IN During a mean follow-up of seven years, 3,454 participants were diagnosed with cancer. When researchers conducted a multivariable analyses of cancer incidence according to levels of IgE, they found that a 10-fold higher level of IgE conferred only a slightly higher risk of developing any cancer, but, as they hypothesized, wassignificantly
ON LOCATION ARCHIVES Visit our On Location category - Page 50 of 50. ASH Clinical News.Contact us today
LETERMOVIR PREVENTS CYTOMEGALOVIRUS INFECTION AND IMPROVES Prophylactic treatment with letermovir improved overall survival (OS) and significantly decreased the incidence of clinically significant cytomegalovirus (CMV) infection in patients who underwent allogeneic hematopoietic cell transplantation (alloHCT), according to results from a single-center study presented at the 2021 American Society of Clinical Oncology Annual Meeting. ISATUXIMAB PLUS CARFILZOMIB: A NEW STANDARD FOR RELAPSED The three-drug combination of the CD38-targeting antibody isatuximab plus carfilzomib and dexamethasone significantly improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma, compared with carfilzomib and dexamethasone alone, according to interim analysis data from the IKEMAtrial.
ACUTE LEUKEMIAS ARCHIVES Visit our Acute Leukemias category - Page 15 of 15. ASH Clinical News.Contact us today
THE SIGNIFICANCE OF JAK2-POSITIVE TEST RESULTS IN A Majid Shojania, MD. Winnipeg, Canada. JAK2 mutation should not be present in the normal population; it is a sign of a hematologic condition but not specific. It is more common in patients with polycythemia vera or myelofibrosis but also can be seen in those with myelodysplastic syndromes (MDS) andASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITHBLOOD DISORDER MGUSLIFE EXPECTANCY FOR MGUS PATIENTSMGUS BLOOD CONDITIONMGUS SYMPTOMS FATIGUESIGNS THAT MGUS IS PROGRESSINGSYMPTOMS OF MGUS DISEASE Understanding Bone Disease and Fractures in Patients With MGUS - Blood Advances in a Different Vein, From the Blood Journals, News - ASHClinical News
R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News MORE REASONS TO BECOME A HEMATOLOGIST… In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology).After sharing the results of an entirely non-scientific survey of his colleagues (such as “I experienced a strange thrill after using the longest needles ever made” and “I misspelled WILL REPLACING BLEOMYCIN WITH BRENTUXIMAB VEDOTIN For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen and replacing it with brentuximab vedotin and AVD (A+AVD) could prolong modified progression-free survival (mPFS). PATIENT EDUCATION UNDERSTANDING VON WILLEBRAND DISEASEHOW TO DIAGNOSE VON WILLEBRAND DISEASESYMPTOMS OF VON WILLEBRAND DISEASEVON WILLEBRAND DISEASE UPTODATEVON WILLEBRAND DISEASE IN CHILDRENVON WILLEBRAND DISEASE IN DOGSVON WILLEBRAND DISEASE IN GIRLS What Are the Symptoms of vWD? People with vWD experience frequent nosebleeds, easy bruising, and excessive bleeding during and after inva-sive procedures, such as tooth extractions and surgery. PATIENT EDUCATION WHAT IS MULTIPLE MYELOMA?PATIENT EDUCATION FOR NEWLYDIAGNOSED MULT…
What is Multiple Myeloma? Multiple myeloma starts in the plasma cells in bone mar-row. The bone marrow is the soft, spongy tissue found in the center of many bones where blood cells are produced.ASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITHBLOOD DISORDER MGUSLIFE EXPECTANCY FOR MGUS PATIENTSMGUS BLOOD CONDITIONMGUS SYMPTOMS FATIGUESIGNS THAT MGUS IS PROGRESSINGSYMPTOMS OF MGUS DISEASE The findings, though, appear to raise more questions than they answer. While individuals with MGUS had normal bone-mineral density (BMD), their bone volume was increased compared to patients without MGUS. In addition, men with MGUS had an almost 50% increased risk of fractures, compared with other men. “Our findings suggest an effect of MGUS R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News WILL REPLACING BLEOMYCIN WITH BRENTUXIMAB VEDOTIN For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen and replacing it with brentuximab vedotin and AVD (A+AVD) could prolong modified progression-free survival (mPFS). MORE REASONS TO BECOME A HEMATOLOGIST… More Reasons to Become a Hematologist. Sunday, May 1, 2016. In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology). After sharing the results of an entirely non-scientific survey of hiscolleagues
PATIENT EDUCATION UNDERSTANDING VON WILLEBRAND DISEASEHOW TO DIAGNOSE VON WILLEBRAND DISEASESYMPTOMS OF VON WILLEBRAND DISEASEVON WILLEBRAND DISEASE UPTODATEVON WILLEBRAND DISEASE IN CHILDRENVON WILLEBRAND DISEASE IN DOGSVON WILLEBRAND DISEASE IN GIRLS What Are the Symptoms of vWD? People with vWD experience frequent nosebleeds, easy bruising, and excessive bleeding during and after inva-sive procedures, such as tooth extractions and surgery. PATIENT EDUCATION WHAT IS MULTIPLE MYELOMA?PATIENT EDUCATION FOR NEWLYDIAGNOSED MULT…
What is Multiple Myeloma? Multiple myeloma starts in the plasma cells in bone mar-row. The bone marrow is the soft, spongy tissue found in the center of many bones where blood cells are produced. MEDICARE SEQUESTRATION DELAY EXTENDED THROUGH 2021 Medicare Sequestration Delay Extended Through 2021 - Latest & Greatest, News, Online Exclusives - ASH Clinical News FDA BRINGS BACK UNAPPROVED DRUGS INITIATIVE The U.S. Food and Drug Administration (FDA) is reversing the Trump administration’s decision to end the Unapproved Drugs Initiative. This program, which launched in 2006, requires pharmaceutical manufacturers to seek approval for drugs that were never approved but were on the market because they predated stricter regulatoryrequirements.
GENOME GENETICS DNA MOONSHOT PERSONALIZED TREATMENT 2021 L Street NW, Suite 900, Washington, DC 20036 Phone 202-776-0544 |Fax 202-776-0545
PRINT SUBSCRIPTION
Subscribe to ASH Clinical News!. ASH Clinical News is your source for worldwide news and perspectives on hematology/oncology.. Published 15 times per year, ASH Clinical News provides American Society of Hematology members and non-members alike with the latest updates in the field, including: • on-site conference reporting • coverage of the latest trials published in the Blood journals BIDEN ADMINISTRATION REQUESTS $13.5 BILLION INCREASE IN As part of the administration’s $6 trillion budget request for the 2022 fiscal year, President Joe Biden has proposed a 9% increase, or $13.5 billion, in federal spending on research and development. This includes an increase of 10%, or $4.4 billion, in spending on basic research and 14%, or $6.3 billion, on applied research. LETERMOVIR PREVENTS CYTOMEGALOVIRUS INFECTION AND IMPROVES Prophylactic treatment with letermovir improved overall survival (OS) and significantly decreased the incidence of clinically significant cytomegalovirus (CMV) infection in patients who underwent allogeneic hematopoietic cell transplantation (alloHCT), according to results from a single-center study presented at the 2021 American Society of Clinical Oncology Annual Meeting. ON LOCATION ARCHIVES Visit our On Location category - Page 50 of 50. ASH Clinical News.Contact us today
THE SIGNIFICANCE OF JAK2-POSITIVE TEST RESULTS IN A The significance of JAK2-positive test results in a healthy patient - From Our Readers, MDS & Myeloproliferative Neoplasms, Viewpoints, You Make the Call: Readers' Response - ASH Clinical News ACUTE LEUKEMIAS ARCHIVES Visit our Acute Leukemias category - Page 15 of 15. ASH Clinical News.Contact us today
MORE REASONS TO BECOME A HEMATOLOGIST… In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology).After sharing the results of an entirely non-scientific survey of his colleagues (such as “I experienced a strange thrill after using the longest needles ever made” and “I misspelledASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITHBLOOD DISORDER MGUSLIFE EXPECTANCY FOR MGUS PATIENTSMGUS BLOOD CONDITIONMGUS SYMPTOMS FATIGUESIGNS THAT MGUS IS PROGRESSINGSYMPTOMS OF MGUS DISEASE Understanding Bone Disease and Fractures in Patients With MGUS - Blood Advances in a Different Vein, From the Blood Journals, News - ASHClinical News
R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News MORE REASONS TO BECOME A HEMATOLOGIST… In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology).After sharing the results of an entirely non-scientific survey of his colleagues (such as “I experienced a strange thrill after using the longest needles ever made” and “I misspelled WILL REPLACING BLEOMYCIN WITH BRENTUXIMAB VEDOTIN For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen and replacing it with brentuximab vedotin and AVD (A+AVD) could prolong modified progression-free survival (mPFS). PATIENT EDUCATION UNDERSTANDING VON WILLEBRAND DISEASEHOW TO DIAGNOSE VON WILLEBRAND DISEASESYMPTOMS OF VON WILLEBRAND DISEASEVON WILLEBRAND DISEASE UPTODATEVON WILLEBRAND DISEASE IN CHILDRENVON WILLEBRAND DISEASE IN DOGSVON WILLEBRAND DISEASE IN GIRLS What Are the Symptoms of vWD? People with vWD experience frequent nosebleeds, easy bruising, and excessive bleeding during and after inva-sive procedures, such as tooth extractions and surgery. PATIENT EDUCATION WHAT IS MULTIPLE MYELOMA?PATIENT EDUCATION FOR NEWLYDIAGNOSED MULT…
What is Multiple Myeloma? Multiple myeloma starts in the plasma cells in bone mar-row. The bone marrow is the soft, spongy tissue found in the center of many bones where blood cells are produced.ASH CLINICAL NEWS
ASH Clinical News is a new magazine for American Society of Hematology, offering news and views for the broader hematology/oncology community FDA COMMITTEE VOTES TO WITHDRAW TWO ACCELERATED APPROVALS The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with CARTITUDE-1: MYELOMA CAR T-CELL THERAPY PRODUCES DEEP AND A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated multiple myeloma (MM), according to preliminary data from the phase Ib/II CARTITUDE-1 trial.Deepu Madduri,MD,
UNDERSTANDING BONE DISEASE AND FRACTURES IN PATIENTS WITHBLOOD DISORDER MGUSLIFE EXPECTANCY FOR MGUS PATIENTSMGUS BLOOD CONDITIONMGUS SYMPTOMS FATIGUESIGNS THAT MGUS IS PROGRESSINGSYMPTOMS OF MGUS DISEASE Understanding Bone Disease and Fractures in Patients With MGUS - Blood Advances in a Different Vein, From the Blood Journals, News - ASHClinical News
R2CHOP BENEFITS PATIENTS WITH UNTREATED DIFFUSE LARGE B For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of progression or death by 34%, according to findings published in the Journal of Clinical Oncology.This “signal-seeking” phase II study, conducted by Grzegorz WHAT IS YOUR APPROACH TO A PATIENT WHO What is your approach to a patient who is referred for an immunofixation showing a “faint band” of monoclonal IgG kappa or IgG lambda? - Education, You Make the Call - ASH Clinical News MORE REASONS TO BECOME A HEMATOLOGIST… In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology).After sharing the results of an entirely non-scientific survey of his colleagues (such as “I experienced a strange thrill after using the longest needles ever made” and “I misspelled WILL REPLACING BLEOMYCIN WITH BRENTUXIMAB VEDOTIN For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen and replacing it with brentuximab vedotin and AVD (A+AVD) could prolong modified progression-free survival (mPFS). PATIENT EDUCATION UNDERSTANDING VON WILLEBRAND DISEASEHOW TO DIAGNOSE VON WILLEBRAND DISEASESYMPTOMS OF VON WILLEBRAND DISEASEVON WILLEBRAND DISEASE UPTODATEVON WILLEBRAND DISEASE IN CHILDRENVON WILLEBRAND DISEASE IN DOGSVON WILLEBRAND DISEASE IN GIRLS What Are the Symptoms of vWD? People with vWD experience frequent nosebleeds, easy bruising, and excessive bleeding during and after inva-sive procedures, such as tooth extractions and surgery. PATIENT EDUCATION WHAT IS MULTIPLE MYELOMA?PATIENT EDUCATION FOR NEWLYDIAGNOSED MULT…
What is Multiple Myeloma? Multiple myeloma starts in the plasma cells in bone mar-row. The bone marrow is the soft, spongy tissue found in the center of many bones where blood cells are produced. MEDICARE SEQUESTRATION DELAY EXTENDED THROUGH 2021 Medicare Sequestration Delay Extended Through 2021 - Latest & Greatest, News, Online Exclusives - ASH Clinical News FDA BRINGS BACK UNAPPROVED DRUGS INITIATIVE The U.S. Food and Drug Administration (FDA) is reversing the Trump administration’s decision to end the Unapproved Drugs Initiative. This program, which launched in 2006, requires pharmaceutical manufacturers to seek approval for drugs that were never approved but were on the market because they predated stricter regulatoryrequirements.
GENOME GENETICS DNA MOONSHOT PERSONALIZED TREATMENT 2021 L Street NW, Suite 900, Washington, DC 20036 Phone 202-776-0544 |Fax 202-776-0545
PRINT SUBSCRIPTION
Subscribe to ASH Clinical News!. ASH Clinical News is your source for worldwide news and perspectives on hematology/oncology.. Published 15 times per year, ASH Clinical News provides American Society of Hematology members and non-members alike with the latest updates in the field, including: • on-site conference reporting • coverage of the latest trials published in the Blood journals BIDEN ADMINISTRATION REQUESTS $13.5 BILLION INCREASE IN As part of the administration’s $6 trillion budget request for the 2022 fiscal year, President Joe Biden has proposed a 9% increase, or $13.5 billion, in federal spending on research and development. This includes an increase of 10%, or $4.4 billion, in spending on basic research and 14%, or $6.3 billion, on applied research. LETERMOVIR PREVENTS CYTOMEGALOVIRUS INFECTION AND IMPROVES Prophylactic treatment with letermovir improved overall survival (OS) and significantly decreased the incidence of clinically significant cytomegalovirus (CMV) infection in patients who underwent allogeneic hematopoietic cell transplantation (alloHCT), according to results from a single-center study presented at the 2021 American Society of Clinical Oncology Annual Meeting. ON LOCATION ARCHIVES Visit our On Location category - Page 50 of 50. ASH Clinical News.Contact us today
THE SIGNIFICANCE OF JAK2-POSITIVE TEST RESULTS IN A The significance of JAK2-positive test results in a healthy patient - From Our Readers, MDS & Myeloproliferative Neoplasms, Viewpoints, You Make the Call: Readers' Response - ASH Clinical News ACUTE LEUKEMIAS ARCHIVES Visit our Acute Leukemias category - Page 15 of 15. ASH Clinical News.Contact us today
MORE REASONS TO BECOME A HEMATOLOGIST… In last month’s Editor’s Corner, Keith Stewart, MBChB, MBA, asked readers why they chose to join the ranks of the International Society of Bloody Cytotoxics (i.e., pursuing a career in hematology).After sharing the results of an entirely non-scientific survey of his colleagues (such as “I experienced a strange thrill after using the longest needles ever made” and “I misspelled__
__ __
__ __
__
__
* Issues__
* Current Issue
* Special Issues
* Viewpoints__
* Editor’s Corner
* Advanced Practice Voices * From Our Readers__ * You Make the Call: Readers’ Response* Guest Commentary
* Letters to the Editor* A Day in the Life
* Notes From the Hill* The Break Room
* Education__
* You Make the Call
* Hematologica Obscura* How I Teach
* How I Treat In Brief * Demystifying the Lab* Practice Update
* Spotlight__
* Feature Articles
* Pulling Back the Curtain * Blood Beyond Borders* pASHions
* Drawing First Blood* HemOnc Link
* Interviews
* News__
* Online Exclusives
* Latest & Greatest
* From the _Blood_ Journals__ * Written in _Blood_ * _Blood Advances_ in a Different Vein* Literature Scan
* ASH Directions
* The Society Pages
* Topic Compilations__* COVID-19 News
* Acute Leukemias
* Chronic Leukemias
* MDS & Myeloproliferative Neoplasms * Multiple Myeloma & Plasma Cell Disorders * Lymphomas & Lymphoid Neoplasia * Bleeding Disorders * Clotting Disorders * Red Blood Cell & Iron Disorders* On Location__
* ASH Annual Meeting * ASH Meeting on Hematologic Malignancies * ASH Meeting on Lymphoma Biology* Other Meetings
* Multimedia__
* Sound Bites
* Meeting Coverage
__
Search
* ASH Home
* About ASH Clinical News* Authors
* Advertising
* Subscribe
* Contact Us
* eNewsletters
* Cookie Settings
* LOG IN
Welcome! Log into your account Forgot your password? Recover your password__
ASH CLINICAL NEWS
* Issues__
*
All Current Issue
Special Issues
JUNE 2021 VOLUME 7 ISSUE 7 MAY 2021 VOLUME 7 ISSUE 6 FOCUS ON MYELOID MALIGNANCIES (VOLUME 7, ISSUE 6.1) APRIL 2021 VOLUME 7 ISSUE 5____
* Viewpoints__
* Editor’s Corner
* Advanced Practice Voices * From Our Readers__ * You Make the Call: Readers’ Response* Guest Commentary
* Letters to the Editor* A Day in the Life
* Notes From the Hill* The Break Room
* Education__
* You Make the Call
* Hematologica Obscura* How I Teach
* How I Treat In Brief * Demystifying the Lab* Practice Update
* Spotlight__
* Feature Articles
* Pulling Back the Curtain * Blood Beyond Borders* pASHions
* Drawing First Blood* HemOnc Link
* Interviews
* News__
* Online Exclusives
* Latest & Greatest
* From the _Blood_ Journals__ * Written in _Blood_ * _Blood Advances_ in a Different Vein* Literature Scan
* ASH Directions
* The Society Pages
* Topic Compilations__* COVID-19 News
* Acute Leukemias
* Chronic Leukemias
* MDS & Myeloproliferative Neoplasms * Multiple Myeloma & Plasma Cell Disorders * Lymphomas & Lymphoid Neoplasia * Bleeding Disorders * Clotting Disorders * Red Blood Cell & Iron Disorders* On Location__
* ASH Annual Meeting * ASH Meeting on Hematologic Malignancies * ASH Meeting on Lymphoma Biology* Other Meetings
* Multimedia__
* Sound Bites
* Meeting Coverage
__ __
PAIN POINTERS
Tuesday, June 1, 2021 Early intervention and careful management are critical in the treatment of peripheral neuropathy Peripheral neuropathy is a common occurrence in patients with hematologic diseases, whether from the disease itself or the chemotherapy used to treat...Read more
ONLINE EXCLUSIVES
WILL THE FDA CRACK DOWN ON CLINICAL TRIAL REPORTING NONCOMPLIANCE? Tuesday, June 1, 2021 The FDA has issued its first notice of noncompliance to Acceleron Pharma for failing to submit clinical trial results to ClinicalTrials.gov, the federal government’s... MEDICARE SEQUESTRATION DELAY EXTENDED THROUGH 2021 Tuesday, June 1, 2021 Following Senate approval, the U.S. House of Representatives voted 384-38 in favor of continuing to delay the return of Medicare sequestration through December 31.... BEAM THERAPEUTICS DEVELOPS INLAID BASE EDITING TECHNIQUE FOR SCD Tuesday, June 1, 2021 WHY ARE WOMEN LEAVING THE HEALTH CARE WORKFORCE? Wednesday, May 26, 2021NEWS
UMBRALISIB DEMONSTRATES LONG-TERM SAFETY AND CLINICAL ACTIVITY IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA Tuesday, June 1, 2021 RIVAROXABAN REDUCES RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION ON HEMODIALYSIS Tuesday, June 1, 2021 COMPARING REAL-WORLD VERSUS CLINICAL TRIAL OUTCOMES FOR ACUTE PROMYELOCYTIC LEUKEMIA Tuesday, June 1, 2021 IDECABTAGENE CILOLEUCEL INDUCES DEEP RESPONSES IN RELAPSED/REFRACTORYMULTIPLE MYELOMA
Saturday, May 1, 2021 FROM THE BLOOD JOURNALS DOES RHEUMATIC DISEASE INCREASE RISK OF MGUS PROGRESSION TO HEMATOLOGIC MALIGNANCIES? Tuesday, June 1, 2021 Patients with monoclonal gammopathy of undetermined significance (MGUS) and concomitant non-antibody (Ab)–mediated inflammatory rheumatic diseases are at increased risk of progression to overtmultiple...
MORE COVID-19 COMPLICATIONS SEEN IN BLACK PATIENTS WITH SICKLE CELLDISEASE...
Tuesday, June 1, 2021 Patients with sickle cell disease (SCD) and sickle cell trait (SCT) have significantly higher rates of hospitalization, pneumonia, and pain related to COVID-19 compared... EVALUATING IBRUTINIB IN PATIENTS WITH HEAVILY PRETREATED HAIRY CELLLEUKEMIA
Tuesday, June 1, 2021 OLDER PATIENTS WITH MYELOMA MAY HAVE SUBOPTIMAL RESPONSE TO COVID-19VACCINATION
Tuesday, June 1, 2021MULTIMEDIA
PAOLO GHIA: IBRUTINIB PLUS VENETOCLAX PRODUCES DEEP RESPONSES INPATIENTS WITH...
Saturday, June 5, 2021 Here, Paolo Ghia, MD, PhD, of Vita-Salute San Raffaele University in Milan, Italy, discusses recent findings from the phase II CAPTIVATE study evaluating fixed-duration... ANN LACASCE: PET ADAPTED THERAPY ALLOWS OMISSION OF RADIATION THERAPYIN...
Friday, June 4, 2021 Ann S. LaCasce, MD, shares data from the Alliance for Clinical Trials in Oncology’s CALGB-50801 trial, which evaluated a PET-adapted approach to cHL therapy. SAAD USMANI: UPDATED RESULTS FROM THE CARTITUDE-1 TRIAL IN PATIENTSWITH...
Friday, June 4, 2021 In this video, Saad Z. Usmani, MBA, MD, discusses updated results from the CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma. DEEPU MADDURI: CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORYMULTIPLE MYELOMA
Wednesday, December 16, 2020 Deepu Madduri, MD, discusses data from the phase Ib/II CARTITUDE-1 study evaluating chimeric antigen receptor (CAR) T cell therapy ciltacabtagene autoleucel in patients with...ON LOCATION
HOW DO PERCEPTIONS ABOUT SIDE EFFECTS INFLUENCE TREATMENT DECISIONS AND OUTCOMES IN AML? Saturday, June 5, 2021 Patients’ negative perception of the side effects of intensive chemotherapy (IC) for acute myeloid leukemia... FIRST-IN-HUMAN STUDY FINDS FF-10101-01 HAS CLINICAL ACTIVITY IN RELAPSED/REFRACTORY FLT3-MUTATED AML Saturday, June 5, 2021 For patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia (AML), treatment with the selective... LETERMOVIR PREVENTS CYTOMEGALOVIRUS INFECTION AND IMPROVES SURVIVALPOST-TRANSPLANT
Saturday, June 5, 2021 Prophylactic treatment with letermovir improved overall survival (OS) and significantly decreased the incidence of clinically... FUNCTIONAL, NUTRITIONAL, AND SOCIAL STATUS PREDICT SURVIVAL OUTCOMES IN OLDER PATIENTS WITH CLL Friday, June 4, 2021 Geriatric domains of functional status, social activity, and nutritional status were associated with overall survival... INVESTIGATING THE COMBINATION OF IVOSIDENIB PLUS VENETOCLAX AND AZACITIDINE IN IDH-MUTATED MYELOID MALIGNANCIES Friday, June 4, 2021 In a small study of patients with IDH1-mutated myeloid malignancies, treatment with ivosidenib plus venetoclax,... CAN PARTICIPATION IN CANCER CLINICAL TRIALS SAVE MONEY? Friday, June 4, 2021 Patients with cancer who were treated as part of a clinical trial hadlower costs...
____
LATEST HEADLINES
VENETOCLAX-BASED TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PULLING BACK THE CURTAIN: CLAIRE MCLINTOCK, MD YOU MAKE THE CALL: HOW WOULD YOU TREAT THIS 38-YEAR-OLD... IMPROVING SICKLE CELL DISEASE OUTCOMES IN SUB-SAHARAN AFRICA STARTS... EDITOR’S CORNER: IT TAKES A VILLAGEAdvertisement
ASH PRESENTS FAQ RESOURCE FOR THROMBOSIS WITH THROMBOCYTOPENIA, ASH NEWS DAILY SEEKS 2021 AUTHORS,... Saturday, May 1, 2021 New COVID-19 Resource: FAQ About Thrombosis with Thrombocytopenia Syndrome The American Society of Hematology (ASH) has released a resource to guide clinicians in recognizing and...SIGN UP FOR OUR
ENEWSLETTER!
Subscribe UnsubscribeEmail Address
First Name
Last Name
Leave this field empty if you're human:* The Society Pages
* Feature Articles
THE SOCIETY PAGES
REMEMBERING THOMAS BROCK, XAVIER BECERRA CONFIRMED AS U.S. HEALTHSECRETARY, AND MORE
Tuesday, June 1, 2021 Remembering Thomas Brock (1926 - 2021) Thomas Brock, PhD, died on April 4, 2021 at the age of 94. Dr. Brock’s discovery of aspecies...
SENATE CONFIRMS SURGEON GENERAL AND ASSISTANT SECRETARY FOR HEALTH, HVO PRESENTS GOLDEN APPLE AWARDS,... Saturday, May 1, 2021 Brian Bolwell Named Chair of Physician Leadership and Development at Cleveland Clinic The Cleveland Clinic has appointed Brian Bolwell, MD, FACP, as chair of physician... REMEMBERING EMIL FREIREICH, MILLIE HUGHES-FULFORD, AND MORE Thursday, April 1, 2021 Remembering Emil Freireich (1927 – 2021) Renowned hematologist and researcher Emil Freireich, MD, died on February 1, 2021, at the age of 93.Dr. Freireich had...FEATURE ARTICLES
PAIN POINTERS
Tuesday, June 1, 2021 Early intervention and careful management are critical in the treatment of peripheral neuropathy Peripheral neuropathy is a common occurrence in patients with hematologic diseases, whether... GENE THERAPY: THE COMEBACK KID OF HEMATOLOGY TREATMENTS? Saturday, May 1, 2021 Despite slow progress and unexpected setbacks, the future of gene therapy remains bright. Ashanthi de Silva was the first human to be treated successfully with...FOUR OF A KIND?
Saturday, May 1, 2021 Soon, there may be as many as four JAK inhibitors available for patients with myelofibrosis. For many of his patients with myelofibrosis, ruxolitinib has been...Recent Posts
* Paolo Ghia: Ibrutinib Plus Venetoclax Produces Deep Responses in Patients with CLL/SLL * How Do Perceptions about Side Effects Influence Treatment Decisions and Outcomes in AML? * First-in-Human Study Finds FF-10101-01 Has Clinical Activity in Relapsed/Refractory FLT3-Mutated AML * Letermovir Prevents Cytomegalovirus Infection and Improves Survival Post-TransplantMEETING COVERAGE
RESEARCHERS VALIDATE BURKITT LYMPHOMA PROGNOSTIC INDEX Monday, March 1, 2021 THIOTEPA-CONTAINING CONDITIONING REGIMENS IMPROVE SURVIVAL OUTCOMES INPATIENTS WITH PCNSL
Monday, March 1, 2021EDITOR'S CORNER
EDITOR’S CORNER: IT TAKES A VILLAGE Tuesday, June 1, 2021 EDITOR’S CORNER: ALL THOSE YESTERDAYS Saturday, May 1, 2021 2021 L Street NW, Suite 900, Washington, DC 20036 Phone 202-776-0544 | Fax 202-776-0545* ASH Home
* Research
* Education
* Advocacy
* Meetings
* Publications
* ASH Store
__ __
__ __
__
Copyright © 2020 by American Society of HematologyContact Us | Terms
of Service | PrivacyPolicy
Generic selectors
Exact matches only
Exact matches only
Search in title
Search in title
Search in content
Search in content
Search in excerpt
Search in posts
Search in posts
Search in pages
Search in pages
Scroll up the results Scroll down the resultsLive Chat is Online
Chatting
0
×
–
undefined
Chat Input Box
Chat
Powered by
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0